Two Phase III trials found that apixaban was more effective for stroke prevention than either aspirin or warfarin in patients with atrial fibrillation (AF), with a similar (versus aspirin ...

aspirin. Apixaban and dabigatran, on the other hand, had similar rates of major bleeding and intracranial hemorrhage compared with aspirin. Researchers reported that apixaban and dabigatran may ...

Further trials comparing aspirin with newer anticoagulants (dabigatran, apixaban and rivaroxaban) are necessary to assess the role of each agent in stroke prevention in patients with AF.

The researchers found that apixaban had similar rates of major bleeding and intracranial hemorrhage compared with aspirin (risk differences, 0.0 [95 percent confidence interval, −1.3 to 2.6] and ...